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LONG-TERM USE OF COLLAGEN HYDROLYSATE AS A
NUTRITIONAL SUPPLEMENT IN ATHLETES WITH
ACTIVITY-RELATED JOINT PAIN
K.R. Flechsenhar1, W. Sebastianelli2
1GELITA AG, Eberbach, Germany; 2Penn State University,
University Park, PA
Purpose: Collagen hydrolysate is a nutritional supplement which
has been shown to exert an anabolic effect on cartilage tissue. Its
administration appears indicated in patients with osteoarthritis.
The purpose of the present study was to investigate the ef-
fect of collagen hydrolysate on individuals who are healthy and
physically active.
Methods: A prospective, randomized, placebo-controlled,
double-blind study was carried out at Penn State University
in University Park (Pennsylvania). Parameters like joint pain,
mobility and inﬂammation were evaluated with the use of a
visual-analogue-scale during a 24-week-study-phase.
Between September 2005 and June 2006, 147 subjects who
competed either on a varsity or a club sport were recruited. Data
of 97 of those 147 subjects could be statistically evaluated.
Seventy-three subjects were randomly assigned to receive 10
grams of collagen hydrolysate per day in the form of a vial
containing 25 ml of a liquid formulation and 74 subjects to
receive a placebo, i.e. a 25 ml of a liquid formulation containing
xanthan.
The primary efﬁcacy parameter was the change of the visual
analogue scales during the study phase in relation to the param-
eters referring to pain, mobility and inﬂammation.
Results: When the data of all the subjects (n = 97) that were
evaluated during the study were taken into consideration, 6
parameters showed statistically signiﬁcant changes of collagen
hydrolysate (CH) versus placebo, namely the parameter “pain at
rest” as assessed by the physician (CH versus placebo (-1,37
± 1.78 versus -0.90 ± 1.74 (p = 0.025))) and the following 5
parameters as assessed by the study participants, “joint pain
when walking” (-1.11 ± 1.98 versus -0.46 ± 1.63 (p = 0.007)),
“joint pain when standing” (-0.97 ± 1.92 versus -0.43 ± 1.74 (p =
0.011)), “joint pain at rest” (-0.81 ± 1.77 versus -0.39 ± 1.56 (p
= 0.039)), “joint pain when carrying objects” (-1.45 ± 2.11 versus
-0.83 ± 1.71 (p = 0.014)) and “joint pain when lifting” (-1.79 ±
2.11 versus -1.26 ± 2.09 (p = 0.018)).
When a sub-group analysis which merely focused on subjects
with knee arthralgia (n = 63) was carried out, the difference
between the effect of collagen hydrolysate versus placebo even
became more pronounced. It was the parameter “joint pain at
rest” which was assessed by the physician with a p = 0.001 (-1.67
± 1.89 versus -0.86 ± 1.77), plus the remaining ﬁve parameters
which were based on the participants’ assessments like “joint
pain when walking” with a p = 0.003 (-1.38 ± 2.12 versus -0.54
± 1.65), “joint pain when standing” with a p = 0.015 (-1.17 ±
2.06 versus -0.50 ± 1.68), “joint pain at rest” with a p = 0.021
(-1.01 ±1.92 versus -0.47 ± 1.63), “joint pain when running a
straight line” with a p = 0.027 (-1.50 ± 1.97 versus -0.80 ± 1.66)
and “joint pain when changing direction” with a p = 0.026 (-1.87
± 2.18 versus -1.20 ± 2.10).
Conclusions: This is the ﬁrst clinical trial to show improvement
of joint-functioning in healthy subjects who were treated with the
nutritional supplement collagen hydrolysate. The results of this
study bear implications on the use of collagen hydrolysate as a
primary-prevention-effort for individuals who are at risk of suf-
fering from degenerative joint disease. Furthermore, the results
also suggest that athletes consuming collagen hydrolysate can
potentially improve their physical performance.
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AUTOLOGOUS CHONDROCYTE IMPLANTATION:
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Purpose: In comparison to conventional surgical treatment and
periosteal autologous chondrocyte implantation (ACI), matrix-
induced ACI (MACI) shows improved clinical outcome and tech-
nical simplicity. However, recent research suggests that the lack
of measurement standardization across these studies, makes re-
liable large scale multi-centre cohort analysis extremely difﬁcult.
Hence, we have conducted both a prospective single-surgeon
cohort study and a retrospective multi-centre satisfaction survey
of over 200 MACI patients.
Methods: Prospective Study:
A consecutive series of 31 implantations were performed in
28 patients (18 male; 10 female) at a minimum of 24 months
(mean age 36.5 years, mean BMI 25.9). Clinical assessment
by the Six-Minute Walk Distance Test, and the self-administered
Knee Injury and Osteoarthritis Outcome Score (KOOS) was con-
ducted preoperatively, and at 3, 6, 12, and 24 postoperatively.
MRI scans were conducted at 3, 12 and 24 months postopera-
tively. The relationship between MRI and functional outcome was
also calculated. Graft failure was assessed postoperatively, both
clinically and radiographically.
Retrospective Study:
Two hundred and two patients, 12 months or greater post-MACI,
were surveryed. Patients with signiﬁcant reoperation (realign-
ment osteotomy etc) or cognitive impairment were excluded. The
questionnaire was comprised of ten questions, based mainly on
pain and symptom relief, functional restoration, quality of life,
and patient satisfaction. Raw answers to the questionnaire were
converted to a point scale to gain an overall satisfaction score
(based on the Lysholm and Cincinnati scores). Clinical outcome
was statistically compared to various cohort variables.
Results: Prospective Study:
Patients demonstrated a signiﬁcant (P<0.001) improvement in
six minute walk distance and all ﬁve KOOS subscales from 3 to
24 months after MACI surgery, with the most substantial gains
noted in the ﬁrst 12 months. Similarly, patients also demon-
strated signiﬁcantly (P<0.001) improved MRI scoring from 3
to 24 months, with post-hoc analysis again demonstrating im-
provement predominantly in the ﬁrst 12 months, then plateauing
thereafter. A moderate to strong relationship was observed be-
tween functional KOOS outcome and structural MRI outcome. A
10% incidence of hypertrophic growth following MACI was also
observed.
Retrospective Study:
A mean age of the surveyed cohort was 36.9±10.7 (range 14-
77) years, male:female sex ratio 114:88, and mean time from
MACI to survey of 22.7±8.61 (range 12-49). Of note, 85% of
patients rated their pain relief following MACI as good/excellent.
94% of patients stated they had the ability to participate in sport
following MACI, 64% of patients reported no swelling after MACI,
81% of patents reported no occurrence of catching/locking, and
82% of patients rated the overall satisfaction of their MACI
outcome as good or excellent. Statistical comparison between
deﬁned cohort variables and overall satisfaction score found
signiﬁcance between: postoperative months (12-24 months vs.
over 24 months, P=0.03), rehabilitation participation (with rehab
vs. without rehab, P=0.007), patient age (under 30 years-old
vs. 30-50 years-old, P=0.001), and defect location (trochlea vs.
patella, P=0.007; medial femoral condyle vs, patella, P=0.03).
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Conclusions: The aforementioned clinical outcomes and com-
parative analysis is essential for furthering our understanding of
the factors which inﬂuence patient outcomes in the treatment of
cartilage injury by autologous chondrocyte implantation therapy
such as MACI.
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EARLY REDUCTION IN ULCER COMPLICATIONS WITH
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Purpose: A 79% reduction in upper gastrointestinal (GI) ul-
cer complications has been reported for lumiracoxib compared
with nonsteroidal anti-inﬂammatory drugs (NSAIDs) (naproxen
or ibuprofen) over 52 weeks in the non-aspirin population of
the Therapeutic Arthritis Research and Gastrointestinal Event
Trial (TARGET). However, guidelines indicate that these agents
should be used for the shortest possible duration. We investi-
gated how early after the start of treatment a signiﬁcant beneﬁt
of lumiracoxib could be detected in TARGET.
Methods: TARGET randomized 18 325 patients >50 years of
age with osteoarthritis (OA) to receive lumiracoxib 400 mg once
daily (4x the recommended dose for OA) vs ibuprofen 800 mg
three times daily or naproxen 500 mg twice daily for 52 weeks in
one of two sub-studies. Randomization was stratiﬁed for age and
low-dose aspirin use. The primary analysis population included
patients not taking low-dose aspirin, comprising n=6950 patients
treated with lumiracoxib and n=6968 with NSAIDs (naproxen,
n=3537; ibuprofen, n=3431). The primary endpoint was the cu-
mulative incidence of blindly and independently adjudicated def-
inite or probable upper GI ulcer complications. The secondary
endpoint was the incidence of deﬁnite or probable upper GI ulcer
complications and symptomatic ulcers (all ulcers). In these anal-
yses, pointwise 95% conﬁdence intervals (CI) were generated
for the between-treatment differences in Kaplan-Meier estimates
(KMEs) for all ulcers and ulcer complications in the non-aspirin
population.
Results: Based on the upper 95% CIs for the difference in
Kaplan-Meier estimates, in the non-aspirin population there was
a signiﬁcant reduction in all ulcers by Day 8 with lumiracoxib
compared with NSAIDs. For ulcer complications, a signiﬁcant re-
duction with lumiracoxib compared with NSAIDs occurred by Day
16. When analyzed by sub-study, the advantage of lumiracoxib
on all ulcers occurred as early as by Day 6 versus naproxen
(Figure 1) and by Day 32 versus ibuprofen. For ulcer complica-
tions, a signiﬁcant reduction was seen with lumiracoxib by Day
14 versus naproxen and Day 33 versus ibuprofen.
Abstract 260 – Table 1. Efﬁcacy of lumiracoxib in the disease severity subgroups at 13 week
Efﬁcacy variable Pair wise Comparison High severity group Medium severity group Low severity group
Estimated difference P-value Estimated difference P-value Estimated difference P-value
(95% CI of difference) (95% CI of difference) (95% CI of difference)
OA pain Lumiracoxib vs placebo -9.30 (-13.25,-5.34) <0.001 -5.48 (-8.41,-2.55) <0.001 -4.74 (-8.44,-1.03) 0.012
Celecoxib vs placebo -6.70 (-11.22,-2.19) 0.004 -4.76 (-8.15,-1.38) 0.006 -4.74 (-9.03,-0.45) 0.030
Lumiracoxib vs celecoxib -2.59 (-6.44,1.25) 0.186 -0.71 (-3.67,2.24) 0.636 0.00 (-3.70,3.71) 0.998
Patient’s global assessment Lumiracoxib vs placebo -9.83 (-13.74,-5.93) <0.001 -8.09 (-10.99,-5.20) <0.001 -4.21 (-7.87,-0.55) 0.024
of disease activity Celecoxib vs placebo -6.63 (-11.09,-2.18) 0.004 -6.10 (-9.45,-2.75) <0.001 -3.47 (-7.72,0.77) 0.109
Lumiracoxib vs celecoxib -3.20 (-7.00,0.60) 0.099 -1.99 (-4.91,0.93) 0.181 -0.74 (-4.40,2.93) 0.694
WOMAC™ total score Lumiracoxib vs placebo -8.08 (-10.86,-5.30) <0.001 -5.26 (-7.32, -3.19) <0.001 -4.11 (-6.72,-1.50) 0.002
Celecoxib vs placebo -5.62 (-8.79,-2.44) <0.001 -4.94 (-7.32,-2.56) <0.001 -3.24 (-6.26,-0.22) 0.036
Lumiracoxib vs celecoxib -2.47 (-5.17,0.24) 0.074 -0.32 (-2.40,1.77) 0.767 -0.87 (-3.48,1.74) 0.513
Figure 1
Conclusions: The long-term GI beneﬁt of lumiracoxib compared
with traditional NSAIDs has been demonstrated previously. How-
ever, even when given for short periods, the selective COX-2
inhibitor lumiracoxib appears to have signiﬁcant GI safety advan-
tages over nonselective NSAIDs.
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Purpose: To evaluate if the efﬁcacy of lumiracoxib 100 mg od and
celecoxib 200 mg od differed in patients with knee osteoarthritis
(OA) as a function of baseline disease severity.
Methods: Data from two 13-week, multicenter, randomized,
double-blind, double-dummy, placebo-controlled studies compar-
ing lumiracoxib 100 mg od with celecoxib 200 mg od and placebo
were combined for efﬁcacy analysis based on baseline disease
severity. The co-primary endpoints included assessment of OA
pain intensity in the target knee (VAS), patient’s global assess-
ment of disease activity (VAS) and WOMAC™ LK3.1 total score
at study end. Disease severity at baseline was deﬁned as high,
medium, or low using the median of the baseline values for
each of the three primary assessments. A patient was classiﬁed
with high baseline disease severity if all 3 baseline values were
greater than their respective median, medium baseline disease
severity if 1 or 2 baseline values were greater than their median
and low baseline disease severity if none of the 3 baseline
